VICI Properties Inc (VICI) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.07 or 0.24% from the prior close of $29.28. The stock opened at $29.33 and ...

Oklo公司最近与人工智能解决方案提供商和数据中心运营商Switch达成协议，未来将为其提供高达12千兆瓦的能源支持。这一发展不仅为Oklo的商业前景打下基础，也让人对其能否在核能市场中占据一席之地充满期待。

智通财经APP获悉，英伟达(NVDA.US)首席执行官黄仁勋将于周一在2025年美国消费电子展(CES)上发表开幕主题演讲。投行Wedbush表示，黄仁勋的演讲可能会聚焦于这家人工智能芯片巨头对人工智能的愿景上。Wedbush分析师Dan ...

Dan Ives, Wedbush Securities global head of tech research, joins CNBC's 'The Exchange' to discuss the looming TikTok ban in ...

Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a price target of $15, down from $47. The firm has removed cibotercept for pulmonary arterial hypertension from the ...

英伟达 (NVDA.US)首席执行官黄仁勋将于周一在2025年美国消费电子展 (CES)上发表开幕主题演讲。投行Wedbush表示，黄仁勋的演讲可能会聚焦于这家人工智能芯片巨头对人工智能的愿景上。

Wedbush also issued estimates for CarMax’s Q3 2026 earnings at $0.92 EPS and FY2027 earnings at $4.70 EPS. Get CarMax alerts: CarMax ( NYSE:KMX – Get Free Report ) last posted its quarterly ...

Wedbush currently has a “Neutral” rating and a $29.00 price target on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.32) per share.

In a report released today, Jay McCanless from Wedbush reiterated a Hold rating on DR Horton (DHI – Research Report), with a price target of $180.00. The company’s shares closed yesterday at ...

Wedbush is not changing the firm’s positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event to disclose lonigutamab Phase 2 data and plans for ...

The popular platform could be banned on Jan. 19 under a federal law, while many parties have expressed interest in buying the ...

Netflix is set to report fourth-quarter results after the closing bell on Tuesday, with Wall Street analysts holding mostly ...